Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02038647
Title Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Millennium Pharmaceuticals, Inc.
Indications

lung small cell carcinoma

Therapies

Paclitaxel

Alisertib

Age Groups: adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL


No variant requirements are available.